Primary care clinicians play a key role in identifying the early signs and symptoms of a rare T-cell lymphoma, breast implant–associated anaplastic large-cell lymphoma (BIA-ALCL), potential complications that they may encounter, and the importance of early referral for surgery as necessary. In this myCME Go podcast, Mark Jewell, MD, of Jewell Plastic Surgery in Eugene, Oregon, emphasizes that not every woman who presents with swelling around a breast implant has BIA-ALCL and provides insight into 2 cases that should strengthen primary care clinicians’ ability to recognize the potential complications associated with breast implants: 1) fluid accumulation due to a ruptured implant, and 2) a group B streptococcal septicemia with fluid accumulation around the implant leading to its removal.
Steven Horwitz, MD, of the Lymphoma Service of Memorial Sloan Kettering Cancer Center, in New York provided additional commentary for this activity.
This curriculum is designed for family physicians, internists, obstetrician-gynecologists, radiologists, nurse practitioners (NPs), and physician assistants (PAs).
After completing the activity, the participant should be better able to:
Describe the newly recognized disease entity known as breast implant–associated anaplastic large-cell lymphoma (BIA-ALCL), its epidemiology, and how it differs from other types of cancer
Outline a role for primary care clinicians in recognizing early signs of the disease and reporting them to plastic surgery specialists and others, including hematologists, oncologists, and radiologists, for multidisciplinary follow-up
Take part in efforts to help educate patients about BIA-ALCL and provide an appropriate perspective on the relative risks of the disease vis-à-vis other benefits and risks of breast implant procedures
Conflicts of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Mark Jewell, MD Private Practice Jewell Plastic Surgery Associate Clinical Professor, Plastic Surgery Oregon Health Science University Eugene, OR
Dr. Jewell is a consultant for Allergan and Solta Medical.
Steven Horwitz, MD Associate Attending, Lymphoma Service, Department of Medicine Memorial Sloan Kettering Cancer Center New York, NY
Dr. Horwitz is a consultant for ADC Therapeutics, Affimed GmbH, Aileron Therapeutics, Celgene, Corvus Pharmaceuticals, Forty Seven Inc., Innate Pharma, Kyowa Hakko Kirin Co. Ltd., miRagen Therapeutics, Mundipharma GmbH, Seattle Genetics, and Takeda. He has received research funding from ADC Therapeutics, Aileron Therapeutics, Celgene, Forty Seven Inc., Infinity Pharmaceuticals/Verastem, Kyowa Hakko Kirin Co. Ltd., Millennium Pharmaceuticals Inc./Takeda Oncology, Seattle Genetics, and Trillium Therapeutics.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
HME designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Allergan and HME do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Allergan or HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.